Scotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results

On January 22, Scotiabank lifted its terms people connected Johnson & Johnson (NYSE:JNJ) to $265 from $230. The steadfast reiterated an Outperform standing aft the company’s Q4 results.

The bigger takeaway was however good J&J seems to beryllium managing its patent pressures. Stelara is already dealing with biosimilar competition, and much challenges are lined up. The institution expects generics to deed Opsumit successful the US successful the 2nd fractional of 2026. Simponi is apt to look contention successful Europe successful the archetypal fractional of that year, with the US perchance pursuing aboriginal on. Even so, the outlook remains steady. At the midpoint of guidance, Johnson & Johnson sees 2026 income increasing astir 6.7%, with adjusted EPS up astir 6.9%.

The portfolio is doing a batch of the dense lifting. By the extremity of 2025, the institution had 28 platforms, each generating astatine slightest $1 cardinal a year. Two newer names person joined that list: the Shockwave intravascular lithotripsy instrumentality and the crab therapy Carvykti. Thirteen brands are present increasing astatine double-digit rates, which gives the concern immoderate existent balance.

There is besides a engaged twelvemonth up connected the pipeline front. Johnson & Johnson is aiming for regulatory approvals connected 5 drugs this twelvemonth and plans to record 2 more. Results from astatine slightest 10 Phase 3 trials are expected arsenic well.

Johnson & Johnson (NYSE:JNJ) operates crossed the healthcare space, with businesses focused connected researching, developing, manufacturing, and selling a wide scope of aesculapian products worldwide.

While we admit the imaginable of JNJ arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Dividend Stocks with Over 8% Yield and Retirement Stock Portfolio: 12 Low Risk Investments

Disclosure: None.